Published in J Immunol on January 01, 2002
Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design. Front Immunol (2014) 1.13
Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination. J Biomed Biotechnol (2012) 1.01
Design and analysis of immune-evading enzymes for ADEPT therapy. Protein Eng Des Sel (2012) 0.95
Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer (2004) 0.89
A human dendritic cell-based method to identify CD4+ T-cell epitopes in potential protein allergens. Environ Health Perspect (2003) 0.87
Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection. PLoS Pathog (2015) 0.82
The T Cell Response to Staphylococcus aureus. Pathogens (2016) 0.75
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol (2010) 2.48
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol (2004) 2.18
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood (2007) 1.86
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes (2002) 1.79
VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Med (2003) 1.79
A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol (2002) 1.78
Fibrinolysis for acute myocardial infarction: the future is here and now. Circulation (2003) 1.68
Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology (2005) 1.62
Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res (2009) 1.57
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55
Tiplaxtinin impairs nutritionally induced obesity in mice. Thromb Haemost (2006) 1.55
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol (2003) 1.54
Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog (2007) 1.41
Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha. Cardiovasc Res (2003) 1.40
Improved generation of germline-competent embryonic stem cell lines from inbred mouse strains. Stem Cells (2003) 1.36
Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood (2005) 1.35
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem (2011) 1.33
Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood (2002) 1.33
Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol (2003) 1.29
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS (2004) 1.28
Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol (2002) 1.26
Identification of the LEDGF/p75 binding site in HIV-1 integrase. J Mol Biol (2006) 1.24
Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation (2005) 1.23
Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology (2002) 1.22
LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One (2011) 1.19
Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Stem Cells (2005) 1.18
Impaired adipose tissue development in mice with inactivation of placental growth factor function. Diabetes (2006) 1.18
Role of Gas6 in erythropoiesis and anemia in mice. J Clin Invest (2008) 1.16
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood (2002) 1.11
Binding of the concave surface of the Sds22 superhelix to the alpha 4/alpha 5/alpha 6-triangle of protein phosphatase-1. J Biol Chem (2002) 1.11
Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem Biophys Res Commun (2005) 1.11
Global regulation of gene expression by OxyR in an important human opportunistic pathogen. Nucleic Acids Res (2012) 1.10
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother (2008) 1.10
Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One (2012) 1.09
Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension. Stem Cells (2008) 1.08
Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE-/- mice. Circ Res (2008) 1.08
Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood (2007) 1.07
A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem (2004) 1.07
Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost (2004) 1.07
Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2002) 1.05
Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood (2002) 1.05
Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Thromb Haemost (2003) 1.04
Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor. Mol Cell Biol (2012) 1.03
Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb Haemost (2002) 1.03
Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. Blood (2002) 1.03
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories. Biochim Biophys Acta (2003) 1.02
Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood (2008) 1.00
Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome. Circulation (2005) 1.00
Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I. Hum Gene Ther (2002) 0.99
Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer. Mol Ther (2005) 0.99
Structural basis for the high Ca2+ affinity of the ubiquitous SERCA2b Ca2+ pump. Proc Natl Acad Sci U S A (2009) 0.99
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood (2006) 0.99
Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation. Arterioscler Thromb Vasc Biol (2007) 0.95
Tuning the size and properties of ClyA nanopores assisted by directed evolution. J Am Chem Soc (2013) 0.95
Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun (2002) 0.94
Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum Gene Ther (2005) 0.94
The dead-end elimination method, tryptophan rotamers, and fluorescence lifetimes. Biophys J (2003) 0.93
Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants. Mol Ther (2006) 0.91
Role of Gas-6 in adipogenesis and nutritionally induced adipose tissue development in mice. Arterioscler Thromb Vasc Biol (2005) 0.90
Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation. J Acquir Immune Defic Syndr (2008) 0.89
Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent. Hum Gene Ther (2003) 0.89
Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. Circ Res (2003) 0.88
Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Arterioscler Thromb Vasc Biol (2011) 0.87
An alternate sucrose binding mode in the E203Q Arabidopsis invertase mutant: an X-ray crystallography and docking study. Proteins (2008) 0.87
A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction. J Biol Chem (2003) 0.86
Expression of aggrecan(ases) during murine preadipocyte differentiation and adipose tissue development. Biochim Biophys Acta (2006) 0.86
LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 - 2014). Expert Opin Ther Pat (2014) 0.86
Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary flow reserve and reduced capillary density. Circulation (2002) 0.86
Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. PLoS One (2012) 0.85
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development. Thromb Haemost (2006) 0.85
Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov Today (2008) 0.85
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int J Cancer (2002) 0.85
Experimental indication for the existence of multiple Trp rotamers in von Willebrand Factor A3 domain. Proteins (2004) 0.84
Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty. Cardiovasc Res (2002) 0.83
Biosafety of adenoviral vectors. Curr Gene Ther (2003) 0.83
Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol (2003) 0.83
Preclinical gene therapy studies for hemophilia using adenoviral vectors. Semin Thromb Hemost (2004) 0.82
Tryptophan rotamers as evidenced by X-ray, fluorescence lifetimes, and molecular dynamics modeling. Biophys J (2006) 0.82
Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ibalpha. J Biol Chem (2007) 0.82
Structure based discovery of small molecule suppressors targeting bacterial lysozyme inhibitors. Biochem Biophys Res Commun (2011) 0.81